Literature DB >> 29468556

What Is the Minimum Number of Examined Lymph Nodes After Neoadjuvant Therapy in Rectal Cancer?

Peng Gao1, Yongxi Song1, Yuchong Yang1, Shan Zhao1, Yu Sun1, Jingxu Sun1, Xiaowan Chen1, Zhenning Wang2.   

Abstract

BACKGROUND: To date, no guidelines have standardized the number of examined lymph nodes (eLNs) after neoadjuvant treatment. This study investigated the minimum number of eLNs required for patients with rectal cancer (RC) who received neoadjuvant treatment.
MATERIAL AND METHODS: This study was based on data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database. We included 2173 patients with RC who received neoadjuvant therapy. Restricted cubic spline was used to analyze the association between eLNs and lymph node metastasis (LNM).
RESULTS: The number of eLNs was an independent predictive factor for the presence of LNM (odds ratio 1.033; 95% confidence interval 1.020-1.046; P < 0.001). When the number of eLN ≤ 16, 10 and 11 eLNs had the highest rates of positive LNM. Analysis of the restricted cubic spline method found that when number of eLNs was < 10, the LNM rate increased rapidly, but this increase was not so obviously when there were > 10 eLNs.
CONCLUSIONS: Among RC patients who receive neoadjuvant therapy, the minimum number of eLNs may be 10 to ensure pathological quality.

Entities:  

Keywords:  Lymph nodes; Neoadjuvant therapy; Rectal neoplasms

Mesh:

Year:  2018        PMID: 29468556     DOI: 10.1007/s11605-018-3717-x

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  33 in total

1.  Upstaging of early colorectal cancers following improved lymph node yield after methylene blue injection.

Authors:  Rikke Karlin Jepsen; Peter Ingeholm; Eva Løbner Lund
Journal:  Histopathology       Date:  2012-07-17       Impact factor: 5.087

2.  Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: results of study CAO/ARO/AIO-94.

Authors:  Rainer Fietkau; Claus Rödel; Werner Hohenberger; Rudolf Raab; Clemens Hess; Torsten Liersch; Heinz Becker; Christian Wittekind; Matthias Hutter; Eva Hager; Johann Karstens; Hermann Ewald; Norbert Christen; Michael Jagoditsch; Peter Martus; Rolf Sauer
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-29       Impact factor: 7.038

3.  Lymph node retrieval after preoperative chemoradiotherapy for rectal cancer.

Authors:  Daniel C Damin; Mário A Rosito; Paulo C Contu; Cláudio Tarta; Paulo R Ferreira; Lucia M Kliemann; Gilberto Schwartsmann
Journal:  J Gastrointest Surg       Date:  2012-05-23       Impact factor: 3.452

4.  Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: a population-based analysis.

Authors:  Nancy N Baxter; Arden M Morris; David A Rothenberger; Joel E Tepper
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-02-01       Impact factor: 7.038

5.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

6.  Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma.

Authors:  Chiaojung Jillian Tsai; Christopher H Crane; John M Skibber; Miguel A Rodriguez-Bigas; George J Chang; Barry W Feig; Cathy Eng; Sunil Krishnan; Dipen M Maru; Prajnan Das
Journal:  Cancer       Date:  2011-02-15       Impact factor: 6.860

7.  Neoadjuvant therapy for rectal cancer decreases the number of lymph nodes harvested in operative specimens.

Authors:  Robert Amajoyi; Yoori Lee; Patrick J Recio; Philip D Kondylis
Journal:  Am J Surg       Date:  2013-01-22       Impact factor: 2.565

8.  The number of identified lymph node metastases increases continuously with increased total lymph node recovery in pT3 colon cancer.

Authors:  Alexander Törnroos; Stina Garvin; Hans Olsson
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

9.  Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.

Authors:  Yong Sang Hong; Byung-Ho Nam; Kyu-Pyo Kim; Jeong Eun Kim; Seong Joon Park; Young Suk Park; Joon Oh Park; Sun Young Kim; Tae-You Kim; Jee Hyun Kim; Joong Bae Ahn; Seok-Byung Lim; Chang Sik Yu; Jin Cheon Kim; Seong Hyeon Yun; Jong Hoon Kim; Jin-Hong Park; Hee Chul Park; Kyung Hae Jung; Tae Won Kim
Journal:  Lancet Oncol       Date:  2014-09-04       Impact factor: 41.316

10.  Which is the best postoperative chemotherapy regimen in patients with rectal cancer after neoadjuvant therapy?

Authors:  Peng Gao; Yong-xi Song; Jing-xu Sun; Xiao-wan Chen; Ying-ying Xu; Jun-hua Zhao; Xuan-zhang Huang; Hui-mian Xu; Zhen-ning Wang
Journal:  BMC Cancer       Date:  2014-11-27       Impact factor: 4.430

View more
  3 in total

1.  Effects of neoadjuvant chemotherapy plus chemoradiotherapy on lymph nodes in rectal adenocarcinoma.

Authors:  Guillaume Chotard; Maylis Capdepont; Quentin Denost; Denis Smith; Véronique Vendrely; Eric Rullier; Anne Rullier
Journal:  Virchows Arch       Date:  2021-05-13       Impact factor: 4.064

2.  A retrospective study on the impact of the number of resected lymph nodes on the survival outcome of stage IV rectal cancer patients after preoperative therapy.

Authors:  Kexiang Xi; Hui Yu; Kexing Xi
Journal:  J Gastrointest Oncol       Date:  2020-10

3.  A Preoperative Scoring System to Predict the Risk of Inadequate Lymph Node Count in Rectal Cancer.

Authors:  Hao Zhang; Chunlin Wang; Yunxiao Liu; Hanqing Hu; Guiyu Wang
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.